Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
Stocks · News reference
Leerink Partners Initiates Coverage On Freenome with Outperform Rating, Announces Price Target of $18
Leerink Partners analyst Puneet Souda initiates coverage on Freenome (NASDAQ:FRNM) with a Outperform rating and announces Price Target of $18.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Watching Freenome; Traders Circulate Unconfirmed Analyst Comments Suggesting Carelon Healthcare Services (ELV) Just Updated Clinical Guideline Reimbursements To Include Freenome’s SimpleScreen
Gap Posts Upbeat Q2 Earnings, Joins Solstice Advanced Materials, N-Able And Other Big Stocks Moving Higher On Friday
U.S. stocks mixed, Nasdaq falls 0.1%. Gap Inc shares rise 15.2% on strong earnings and raised guidance. Other big gainers include Elastic NV, Solstice Advanced Materials Inc, and Pagerduty Inc.
Guggenheim Initiates Coverage On Freenome with Buy Rating, Announces Price Target of $21
Guggenheim analyst Subbu Nambi initiates coverage on Freenome (NASDAQ:FRNM) with a Buy rating and announces Price Target of $21.